Return to homepagePandemic Pact

Biomarkers of ACE2 inhibition

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-268

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Mark Gurnell

  • Research Location

    United Kingdom

  • Lead Research Institution

    MRC Metabolic Diseases Unit

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

SARS COV2 binds ACE2 to access cells, ACE2 is a key enzyme in teh breakldown of angiotensin a major stimulus to the hormone aldosterone which controls salt and potoassium homeostasis in the body. We are investigating whether this system is disturbed in COVID19 and whether this contributes to any of the cardiovascular complications of the disease